Modulation of CRC development and progression by GPR15L-dependent effects on lymphocyte infiltration and the intestinal microbiota

Impaired T cell recruitment into intestinal tumors represents one of the greatest problems for successful immune therapy. P13 examines whether activation of the G protein coupled receptor GPR15 expressed on T cells which are homing to the large intestine may represent a novel strategy for CRC therapy. Expression of GPR15L, the GPR15 ligand, is reduced both in murine and human CRC. Intriguingly, GPR15L does not only act on T cells but also modulates the intestinal microbiome and suppresses directly tumor cell proliferation and represents therefore a very attractive molecule that could shape a tumor suppressive TME.